<DOC>
	<DOC>NCT02060604</DOC>
	<brief_summary>The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production.</brief_summary>
	<brief_title>Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1. ability to provide written informed consent and comply with study assessments for the full duration of the study; 2. age &gt;40 years; 3. presence of treatmentna√Øve neovascular AMD with a visual acuity between 20/25 and 20/200 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Inclusion criteria for AMD were neovascularisation, fluid, or haemorrhage under the fovea. 1. any previous intravitreal treatment; 2. previous laser treatment in the study eye; 3. myopia &gt;7 dioptres in the study eye; 4. concurrent eye disease in the study eye that could compromise visual acuity (eg, diabetic retinopathy, advanced glaucoma); 5. concurrent corneal epithelial disruption or any condition that would affect the ability of the cornea to heal; 6. known sensitivity to any component of the formulations under investigation.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ketorolac</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>wet macular degeneration</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>